NCI division launches biomarker validation trials
BETHESDA, Md.—The National Cancer Institute's Early Detection Research Network will be launching several validation trials this summer for lung, colon and prostate cancer biomarkers that can compare the effectiveness of industry and academic platforms. Biomarker-based diagnostic panels will be evaluated from firms including Somalogic, Laboratory Corporation of America, Exact Sciences, Gen-Probe and Beckman Coulter, and from researchers at institutions including M.D. Anderson Cancer Center and Johns Hopkins University. Researchers hope to have the lung cancer trial running within two months, with plans to begin the colon and prostate cancer trials this summer. The network's Data Managing and Coordinating Center will analyze all data, and the EDRN hopes to complete all three trials within five years.